أعرض في EDS

Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial

التفاصيل البيبلوغرافية
العنوان: Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
المؤلفون: T. Cho, C Berman, Teresa Macarulla, Stephen Clarke, Ghassan K. Abou-Alfa, Juan W. Valle, Jennifer L. Spratlin, E Hitre, Milind Javle, Michael Howland, Susan Moran, Ivan Borbath, C Louvet, Karl Heinz Weiss, D-Y. Oh, Y Ye
المصدر: Web of Science
بيانات النشر: Elsevier BV, 2019.
سنة النشر: 2019
مصطلحات موضوعية: 0301 basic medicine, Oncology, Cisplatin, medicine.medical_specialty, business.industry, Hematology, Malignancy, medicine.disease, Chemotherapy regimen, Gemcitabine, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Fibroblast growth factor receptor, Response Evaluation Criteria in Solid Tumors, Biliary tract, 030220 oncology & carcinogenesis, Internal medicine, Medicine, Progression-free survival, business, medicine.drug
الوصف: TPS4155Background: Cholangiocarcinoma is the most common biliary tract malignancy with approximately 5,000–10,000 new cases annually in the USA. The fibroblast growth factor receptor (FGFR) family ...
تدمد: 0923-7534
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::707cbac0d9531fce2ff2d5f3a4eea3cc
https://doi.org/10.1093/annonc/mdz247.158
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....707cbac0d9531fce2ff2d5f3a4eea3cc
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09237534